Rallybio Corporation Common Stock RLYB
Key Stats
- Today's Range
- $15.97 – $16.26
- 50-Day Range
- $14.21 – $17.57
- 52-Week Range
- $2.55 – $17.57
- Volume
- 34K shs
- Average Volume
- 40K shs
- Market Cap
- $85.65 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.70
- Price / Sales
- 99.83
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $858,000
- Net Income
- $-7,817,000
- Net Margin
- -911.07%
- Return on Equity
- -15.55%
- Debt-to-Equity
- —
About Rallybio Corporation Common Stock
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Related Stocks
Compare head-to-head: RLYB vs LLY·RLYB vs JNJ·RLYB vs ABBV·RLYB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.